GlassScriptPhysician profile
Brian Keith Harris
NPI 1598877359
$1,437.76
in general payments reported to CMS, 2019-2025
28 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $147 · 2021: $94.33 · 2022: $140 · 2023: $203 · 2024: $275 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.12 | 2021-2025 | |
| Amgen INC. | $127.96 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $115.51 | 2019-2025 | |
| Novo Nordisk INC | $100.29 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Jazz Pharmaceuticals INC. | $88.94 | 2022 | |
| Astellas Pharma US INC | $59.92 | 2023-2025 | Veozah |
| Medtronic, INC. | $55.37 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $53.29 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.81 | 2025 | Xifaxan |
| Allergan, INC. | $48.79 | 2020 | |
| Glaxosmithkline, LLC. | $43.83 | 2019-2024 | Arexvy, Shingrix |
| Dexcom, INC. | $41.94 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic USA, INC. | $31.61 | 2019 | |
| Irhythm Technologies, INC. | $31.07 | 2024 | Zio Xt Patch, Zio Monitor |
| Sonex Health, INC. | $27.86 | 2022-2024 | Sx-One Microknife |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $25.10 | 2019-2021 | |
| Verona Pharma, INC. | $23.76 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $22.83 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $22.05 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $21.49 | 2025 | |
| Exact Sciences Corporation | $17.09 | 2024 | Cologuard Collection Kit |
| Cranial Technologies, INC | $16.46 | 2019 | |
| Cardiovascular Systems INC. | $16.34 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.54 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.29 | 2025 | Xhance, Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.51 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.